Efficacy of oats in dyslipidemia: a systematic review and meta-analysis
Anqi Li,Jing Gao,Yingcai Li,Shihao Qi,Tiantian Meng,Shanshan Yu,yuqing Zhang,Yingyong He,Yuqing Zhang,Qingyong He
DOI: https://doi.org/10.1039/d3fo04394k
IF: 6.3173
2024-03-06
Food & Function
Abstract:Background : In recent years, oats' effect on lowering serum cholesterol has been recognized. However, no systematic reviews summarized the effect of daily consumption of oat-based products on serum lipids in patients with dyslipidemia. Methods : We searched eight databases and two clinical trial registries from inception to July 31, 2023. We included randomized controlled trials (RCTs) evaluating the efficacy of oat-based products (≥4 weeks) on lipid levels or cardiovascular events in patients with dyslipidemia. Two authors independently screened articles, extracted data and assessed the risk of bias of included studies with Cochrane risk-of-bias tool 2.0. We used STATA 17.0 to conduct meta-analysis and Grading of Recommendations Assessment, Development and Evaluation (GRADE) to assess the certainty of evidence. Results : We finally included 17 eligible trials with 1731 subjects. The oat intervention varied from oat β-glucan-based products to oat bran-based products and wholegrain oat. Overall, the risk of bias of included trials was high or some concerns were noted because of the inadequate randomization, allocation concealment, and inappropriate data analysis method. Compared to the placebo or usual diet, one study indicated that oat-based products have no significant difference in major cardiovascular events. Pooled estimates showed that oat-based products may result in a large reduction in LDL-C (WMD, −0.24 mmol L −1 ; 95% CI: −0.33, −0.15) (moderate certainty) and TC (WMD, −0.32 mmol L −1 ; 95% CI: −0.48, −0.17) (moderate certainty). Compared to other diets (mainly other cereals), oat-based products probably reduce the level of LDL-C (WMD, −0.17 mmol L −1 ; 95% CI: −0.25, −0.08) (moderate certainty) and TC (WMD, −0.21 mmol L −1 ; 95% CI: −0.30, −0.12) (moderate certainty). Both groups showed that oat-based products had little effect on HDL-C and TG (moderate certainty). Oat-related adverse events were mostly gastrointestinal such as diarrhea, nausea, and flatulence being the most prevalent. Conclusions : Oat-based products may reduce TC and LDL-C, but have little effect on TG, HDL-C, and major cardiovascular events in patients with dyslipidemia.
biochemistry & molecular biology,food science & technology